Anzeige
Mehr »
Samstag, 04.04.2026 - Börsentäglich über 12.000 News

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2JPMY | ISIN: US64131A1051 | Ticker-Symbol: NRC
Tradegate
02.04.26 | 21:49
1,294 Euro
-2,12 % -0,028
Branche
Gesundheitswesen
Aktienmarkt
Sonstige
1-Jahres-Chart
NEURONETICS INC Chart 1 Jahr
5-Tage-Chart
NEURONETICS INC 5-Tage-Chart
RealtimeGeldBriefZeit
1,3141,32802.04.
1,3081,33602.04.

Aktuelle News zur NEURONETICS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
18.03.Canaccord cuts Neuronetics stock price target on valuation shift11
17.03.Neuronetics outlines >9% 2026 revenue growth target while piloting new TMS models and preparing for Compass therapy launch3
17.03.Neuronetics: EPS verfehlt Schätzungen um 0,01 $ - Umsatz besser als erwartet8
17.03.Neuronetics CEO Keith Sullivan To Step Down; Dan Reuvers Named Successor4
17.03.Neuronetics names Dan Reuvers as CEO effective March 233
NEURONETICS Aktie jetzt für 0€ handeln
17.03.Neuronetics, Inc. - 10-K, Annual Report1
17.03.Neuronetics GAAP EPS of -$0.10 beats by $0.01, revenue of $41.78M beats by $0.94M2
17.03.Neuronetics, Inc. - 8-K, Current Report-
17.03.Neuronetics appoints Dan Reuvers as chief executive officer1
17.03.Neuronetics Reports Fourth Quarter and Full Year 2025 Financial and Operating Results212Total revenue of $41.8 million in Q4 2025, up 86% as reported and 23% on an adjusted pro forma basis versus Q4 2024 Greenbrook clinic revenue of $23.5 million in Q4 2025, up 428% as reported and 37%...
► Artikel lesen
17.03.Neuronetics Appoints Dan Reuvers as President and Chief Executive Officer273MALVERN, Pa., March 17, 2026 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM) (the "Company"), a medical technology company focused on designing, developing, and marketing products that improve...
► Artikel lesen
25.02.Neuronetics, Inc. - 8-K, Current Report5
11.02.Neuronetics Expects Q4 Revenue To Increase 86%; Stock Up24
10.02.Neuronetics, Inc. - 8-K, Current Report1
10.02.Neuronetics reports 86% revenue growth in Q4 20258
10.02.Neuronetics expects Q4 revenue of $41.8 million7
10.02.Neuronetics Announces Selected Preliminary Unaudited Fourth Quarter and Full Year 2025 Financial Results215All values provided represent preliminary unaudited results Fourth quarter 2025 revenue of $41.8 million, representing 86% year-over-year growth on an as reported basis and 23% year-over-year growth...
► Artikel lesen
22.01.Neuronetics, Inc. - 8-K, Current Report5
06.01.Neuronetics, Inc. - 8-K, Current Report5
12.11.25Neuronetics: TRICARE West Expands NeuroStar TMS Coverage to Include Adolescents Aged 15+ Struggling with Depression7
Weiter >>
34 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1